MRD Analytical Validation Working Group

Jimmy Lin, MD, PhD

Chief Scientific Officer

Freenome

Co-Chairs

Jonathan Baden, PhD

Executive Director, Head of Precision Medicine

Bristol Myers Squibb

Mark Sausen, PhD

Head of Technology Innovation

Personal Genome Diagnostics

Current Projects

  • MRD Tumor-Informed AV Protocols (manuscript in peer review, group is no longer meeting)

  • MRD Tumor-Agnostic AV Protocols (FDA pre-submission in preparation)

Participating Organizations

Adela, Association for Molecular Pathology (AMP), AstraZeneca, Bristol Myers Squibb (BMS), Delfi Diagnostics, Exact Sciences, Foundation Medicine, Freenome, Grail, Guardant Health, Horizon Discovery, Illumina, Labcorp, LGC SeraCare, Memorial Sloan Kettering Cancer Center (MSKCC), Meridian Life Sciences, Natera, NeoGenomics, Pfizer, Roche Diagnostics, Tempus, Ultima Genomics, Veracyte

Past Deliverables

Not applicable at this time.

Meetings

This working group meets on zoom for one hour on a bi-weekly basis.

Special workshops and sessions:

Not applicable at this time.